Eliminating hepatitis B virus through neonatal vaccination: Can we make it?

how can we make decision for patients with chronic hepatitis b according to hepatitis b virus (hbv) dna level?

conclusions it is concluded that most hbeag negative hepatitis b patients with serum hbv dna level of 2000-20000 iu/ml, persistent normal alt concentration, and no or mild liver damage on biopsy can be clinically managed as hbv inactive carriers. results two hundred forty-three hbeag negative hepatitis b patients were stratified into three groups based on to their hbv dna level including group ...

We can make it happen

No abstract available.

How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?

BACKGROUND HBeAg negative hepatitis B infection exerts both inactive carrier state and chronic active hepatitis, which are sometimes difficult to differentiate. Serial hepatitis B virus (HBV) DNA quantification, alanine transaminase (ALT) measurement, and liver histology assessment can help to differentiate these forms of hepatitis B infection. OBJECTIVES We aimed to clarify the clinical and ...

The necessity of booster vaccination after neonatal hepatitis B vaccination

Soon after introducing recombinant hepatitis B virus (HBV) vaccine, universal neonatal vaccination became the corner stone of the preventive measures for this potentially life threatening infection (1-3). By 2006 more than 177 out of 193 member states of world health organization (WHO) introduced HBV vaccination in their national infant immunization programs (1). Following a complete series of ...

the necessity of booster vaccination after neonatal hepatitis b vaccination